Plain-English translation of NCT07181720 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing CD70-targeted CAR-T cell therapy, a personalized cancer treatment that uses modified immune cells to recognize and attack tumors. The therapy is being tested in people with advanced cancers (including kidney, lung, thyroid, ovarian, cervical, or thymic cancers) that have not responded to standard treatments. Researchers will test three different ways of delivering the treatment—through an IV infusion, into the space around the lungs, or into the abdominal cavity—to find the safest and most effective dose.
Standard cancer treatments often stop working for patients with advanced solid tumors, leaving few options. This medication represents a new approach using the body's own immune system to target cancer cells, offering hope for patients who have run out of conventional treatment choices.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first have blood drawn so doctors can collect and expand your immune cells in the laboratory. You will then receive the modified cells back into your body through one of three delivery methods (as an IV infusion, or directly into the space around your lungs or abdomen, depending on which group you're assigned to). The trial has two phases: an initial dose-finding phase to determine the safest dose, followed by a larger phase to confirm safety and measure how well the treatment works. You will have follow-up visits and imaging scans to monitor your response.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China